Comment: Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine [3] (multiple letters)

Mong-Liang Lu, Winston W. Shen, Igor Schillevoort, Anthonius De Boer, Raymund A.C. Roos, Paul A.F. Jansen, Hubert G.M. Leufkens

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Pages (from-to)1292-1293
Number of pages2
JournalAnnals of Pharmacotherapy
Volume36
Issue number7-8
Publication statusPublished - 9 Mar 2002

Keywords

  • dopamine 2 receptor
  • haloperidol
  • olanzapine
  • risperidone
  • drug efficacy
  • drug potency
  • extrapyramidal symptom
  • human
  • incidence
  • letter
  • priority journal
  • receptor occupancy
  • risk assessment

Cite this